Showing results (581-590 of 673) with videos related to
Sort By:
Pageof 68
HIV Clinical Trials|April 17, 2007
Resistance costs and future drug options of antiretroviral therapies: analysis of the role of NRTIs, NNRTIs, and PIs in a large clinical cohortFranco Maggiolo, Diego Ripamonti, Monica Airoldi, et al.HIV Clinical Trials|April 17, 2007
Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) studyCalvin J Cohen, Amy E Colson, Alexander G Sheble-Hall, et al.HIV Clinical Trials|April 17, 2007
Pravastatin in HIV-infected patients treated with protease inhibitors: a placebo-controlled randomized studyFabrice Bonnet, Valerie Aurillac-Lavignolle, Dominique Breilh, et al.HIV Clinical Trials|April 25, 2006
Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrationsDon E Smith, Sarangapany Jeganathan, John RayHIV Clinical Trials|July 11, 2007
Predictors of AIDS-defining events among advanced naïve patients after HAARTCarlo Torti, Giuseppe Lapadula, Franco Maggiolo, et al.HIV Clinical Trials|July 11, 2007
Analysis of treatment costs for HIV RNA reductions and CD4 increases for darunavir versus other antiretrovirals in treatment-experienced, HIV-infected patientsAndrew M Hill, Colette SmithHIV Clinical Trials|July 11, 2007
Improved survival in HIV-associated diffuse large B-cell lymphoma with the addition of rituximab to chemotherapy in patients receiving highly active antiretroviral therapyH Ezzat, D Filipenko, L Vickars, et al.HIV Clinical Trials|July 11, 2007
Effects of HIV infection on body composition changes among men of different racial/ethnic originsFehmida Visnegarwala, Judith C Shlay, Vaughn Barry, et al.HIV Clinical Trials|August 28, 2007
High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of responseDaniel Podzamczer, Martin S King, Cheri E Klein, et al.HIV Clinical Trials|August 28, 2007
Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overviewJohn A Bartlett, Shan-Shan Chen, Joseph B QuinnPageof 68